Serious Side Effects: In some rare cases, semaglutide can cause serious problems with your pancreas, gallbladder, or kidneys
Securing substantial funding for large-scale clinical trials will be a major determinant of its future
Real evidence: A 12-week study: submaximal semaglutide improved metabolic markers but showed no change in the inflammatory markers IL-6, TNF-, or PAI-1 Semaglutide dose-response studies: effects require 0.2 mg/day, and even those effects are diminished when adjusted for weight change Meta-analyses showing anti-inflammatory effects correlate with improvements in insulin resistance and weight loss, not with microdosing voodoo magic
T max , time to peak concentration of drug in plasma
Theyre ushering in a new standard of care and a renewed push towards innovation in metabolic conditions and beyond
fighting another pandemic